The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS -Mutant Lung Adenocarcinoma
Open accessPublished version of a preprint
Abstract
In KRAS-mutant lung adenocarcinoma, tumors with LKB1 loss (KL) are highly enriched for concurrent KEAP1 mutations, which activate the KEAP1/NRF2 pathway (KLK). Here, we investigated the biological consequences of these cooccurring alterations and explored whether they conferred specific therapeutic vulnerabilities. Compared with KL tumors, KLK tumors exhibited increased expression of genes involved in glutamine metabolism, the tricarboxylic acid cycle, and the redox homeostasis signature. Using isogenic pairs with knockdown or overexpression of LKB1, KEAP1, and NRF2, we found that LKB1 loss results in increased energetic and redox stress marked by increased levels of intracellular reactive oxygen species and decreased levels of ATP, NADPH/NADP+ ratio, and glutathione. Activation of the KEAP1/NRF2 axis in LKB1-deficient cells enhanced cell survival and played a critical role in the maintenance of energetic and redox homeostasis in a glutamine-dependent manner. LKB1 and the KEAP1/NRF2 pathways cooperatively drove metabolic reprogramming and enhanced sensitivity to the glutaminase inhibitor CB-839 in vitro and in vivo. Overall, these findings elucidate the adaptive advantage provided by KEAP1/NRF2 pathway activation in KL tumors and support clinical testing of glutaminase inhibitor in subsets of KRAS-mutant lung adenocarcinoma. Significance: In KRAS-mutant non–small cell lung cancer, LKB1 loss results in enhanced energetic/redox stress, which is tolerated, in part, through cooccurring KEAP1/NRF2–dependent metabolic adaptations, thus enhancing glutamine dependence and vulnerability to glutaminase inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we did not identify targets related to pathways previously investigated for STK11-mutant cancer therapy, such as glutamine synthesis (37) or mTOR signaling (38, 39).”
From TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy (2025) · cites this paper as [37]
Experimental — accuracy not yet measuredIn the citing paper
“Separately, the loss of LKB1 in mutant KRAS non-small cell lung cancer preclinical mouse model was found to promote NRF2-dependent metabolic alterations that increased the tumor cells’ dependence on glutamine and created a vulnerability to glutaminase inhibition66.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [66]
In the citing paper
“Thus, cancer cells harboring KRAS, KEAP1 and LKB1 mutations may be more sensitive to glutaminase inhibition compared to normal counterparts66.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [66]
In the citing paper
“Thus, NRF2- mediated metabolic reprogramming and regulation of redox homeostasis likely underpin the strong co-selection of KEAP1 with LKB1 and KRAS mutations in NSCLC at least partially because oncogenic KRAS itself promotes oxidative stress and anabolic metabolism and because KL NSCLC cells depend on the pentose phosphate pathway for NAPDH generation and for detoxification of reactive oxygen”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vichai, V., & Kirtikara, K. (2006) · Nature Protocols · doi:10.1038/nprot.2006.179 · Cited by 3,679
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Self-citationTranscriptional Regulation by Nrf2
Tonelli, C., Chio, I. I. C., & Tuveson, D. A. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7342 · Cited by 2,264
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova‐Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,201
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 3×
“Because NRF2 has been reported to activate genes involved in PPP and purine nucleotide production (22), and glutamine is needed in this process, we treated cells with exogenous nucleotides to determine whether they could compensate for the effects of glutaminase inhibition.”
The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer
Kansanen, E., Kuosmanen, S. M., Leinonen, H., & Levonen, A.-L. (2013) · Redox Biology · doi:10.1016/j.redox.2012.10.001 · Cited by 1,313
Cited by
Sorted by citations
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Self-citationCystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Koppula, P., Zhuang, L., & Gan, B. (2020) · Protein & Cell · doi:10.1007/s13238-020-00789-5 · Cited by 2,590
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Self-citationRicciuti, B., Arbour, K. C., Lin, J. J., Vajdi, A., Vokes, N., Hong, L., Zhang, J., Tolstorukov, M. Y., Li, Y. Y., Spurr, L. F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.013 · Cited by 394
Self-citationThe metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer
Adinolfi, S., Patinen, T., Deen, A. J., Pitkänen, S., Härkönen, J., Kansanen, E., Küblbeck, J., & Levonen, A. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102726 · Cited by 319
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy
Yang, W., Qiu, Y., Stamatatos, O. T., Janowitz, T., & Lukey, M. J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.003 · Cited by 308
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E. C., Huang, C., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01313-4 · Cited by 299
The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
Jyotsana, N., Ta, K. T. L., & DelGiorno, K. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.858462 · Cited by 287
Wohlhieter, C. A., Richards, A. L., Uddin, F. Z., Hulton, C. H., Quintanal-Villalonga, À., Martin, A. S., de Stanchina, E., Bhanot, U. K., Asher, M., Shah, N., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108444 · Cited by 247
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T. Y., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 242
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 246
Squamous cell lung cancer: Current landscape and future therapeutic options
Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.018 · Cited by 215
MCT4-Dependent Lactate Secretion Suppresses Antitumor Immunity in LKB1-Deficient NSCLC
Qian, Y., Galán‐Cobo, A., Guijarro, I., Dang, M., Molkentine, D. P., Poteete, A., Zhang, F., Wang, Q., Wang, J., Parra, E. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2023.05.015 · Cited by 206
Self-citationThe pleiotropic functions of reactive oxygen species in cancer
Wu, K., Zowalaty, A. E. E., Sayin, V. I., & Papagiannakopoulos, T. Y. (2024) · Nature Cancer · doi:10.1038/s43018-024-00738-9 · Cited by 207
Antioxidant Therapy in Cancer: Rationale and Progress
Luo, M., Zhou, L., Huang, Z., Li, B., Nice, E. C., Xu, J., & Huang, C. (2022) · Antioxidants · doi:10.3390/antiox11061128 · Cited by 203
NRF2: KEAPing Tumors Protected
Pillai, R., Hayashi, M., Zavitsanou, A.-M., & Papagiannakopoulos, T. Y. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0922 · Cited by 192
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature · doi:10.1038/s41586-024-07943-7 · Cited by 194
Self-citationWang, Z., Liu, F., Fan, N., Zhou, C., Li, D., MacVicar, T., Dong, Q., Bruns, C. J., & Zhao, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589508 · Cited by 189
Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer
Best, S. A., Gubser, P. M., Sethumadhavan, S., Kersbergen, A. J., Abril, Y. L. N., Goldford, J. E., Sellers, K., Abeysekera, W., Garnham, A. L., McDonald, J. A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.04.003 · Cited by 188
Jin, H., Wang, S., Zaal, E. A., Wang, C., Wu, H.-Q., Bosma, A. R., Jochems, F., Isima, N., Jin, G., Lieftink, C., et al. (2020) · eLife · doi:10.7554/elife.56749 · Cited by 183
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
Bartolacci, C., Andreani, C., do Vale, G. D., Berto, S., Melegari, M., Crouch, A. C., Baluya, D. L., Kemble, G. W., Hodges, K. B., Starrett, J. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31963-4 · Cited by 183
Self-citationBinkley, M. S., Jeon, Y.-J., Nesselbush, M. C., Moding, E. J., Nabet, B. Y., Almanza, D., Kunder, C. A., Stehr, H., Yoo, C. H., Rhee, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0282 · Cited by 165
The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies
Jaganjac, M., Milković, L., Šunjić, S. B., & Žarković, N. (2020) · Antioxidants · doi:10.3390/antiox9111151 · Cited by 167
Potential Applications of NRF2 Modulators in Cancer Therapy
Panieri, E., Djordjević, A. B., Telkoparan‐Akillilar, P., Cevik, D., Kouretas, D., Veskoukis, A. S., Skaperda, Z., Tsatsakis, A. M., Wallace, D., Süzen, S., et al. (2020) · Antioxidants · doi:10.3390/antiox9030193 · Cited by 167
Glutathione and its precursors in cancer
Asantewaa, G., & Harris, I. S. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.03.001 · Cited by 158
Mechanisms of and Potential Medications for Oxidative Stress in Ovarian Granulosa Cells: A Review
Liu, S., Jia, Y., Meng, S., Luo, Y., Yang, Q., & Pan, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119205 · Cited by 169
Targeting Glutathione Metabolism: Partner in Crime in Anticancer Therapy
Desideri, E., Ciccarone, F., & Ciriolo, M. R. (2019) · Nutrients · doi:10.3390/nu11081926 · Cited by 155
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Zavitsanou, A., Pillai, R., Yuan, H., Wu, W., Bartnicki, E., Karakousi, T. R., Rajalingam, S., Herrera, A. M., Karatza, A., Rashidfarrokhi, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113295 · Cited by 157
Clinical development of metabolic inhibitors for oncology
Lemberg, K. M., Gori, S. S., Tsukamoto, T., Rais, R., & Slusher, B. S. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148550 · Cited by 142
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 145
Sánchez-Ortega, M., Carrera, A. C., & Garrido, A. (2021) · Cells · doi:10.3390/cells10081879 · Cited by 130
CREB stimulates GPX4 transcription to inhibit ferroptosis in lung adenocarcinoma
Wang, Z., Zhang, X., Tian, X., Yang, Y., Ma, L., Wang, J., & Yu, Y. (2021) · Oncology Reports · doi:10.3892/or.2021.8039 · Cited by 122
Self-citationKRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Lim, T. K. H., Skoulidis, F., Kerr, K. M., Ahn, M., Kapp, J. R., Soares, F. A., & Yatabe, Y. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107293 · Cited by 131
Self-citationMetabolic Regulation of Redox Balance in Cancer
Purohit, V., Simeone, D. M., & Lyssiotis, C. A. (2019) · Cancers · doi:10.3390/cancers11070955 · Cited by 120
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Foggetti, G., Li, C., Cai, H., Hellyer, J. A., Lin, W.-Y., Ayeni, D. O., Hastings, K., Choi, J., Wurtz, A., Andrejka, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1385 · Cited by 111
Sitthideatphaiboon, P., Galán‐Cobo, A., Negrao, M. V., Qu, X. H., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2859 · Cited by 115
Self-citationSTK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
Tostivint, E. P., Lugat, A., Fontenau, J.-F., Denis, M. G., & Bennouna, J. (2021) · Cells · doi:10.3390/cells10113129 · Cited by 107
Ferroptosis and EMT: key targets for combating cancer progression and therapy resistance
Ren, Y., Mao, X., Xu, H. J., Dang, Q., Weng, S., Zhang, Y., Chen, S., Liu, S., Ba, Y., Zhou, Z., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04907-4 · Cited by 116
Starve Cancer Cells of Glutamine: Break the Spell or Make a Hungry Monster?
Jiang, J., Srivastava, S., & Zhang, J. (2019) · Cancers · doi:10.3390/cancers11060804 · Cited by 108
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
Santarpía, M., Aguilar, A., CHAIB-OUKADOUR, I., Cardona, A. F., Fancelli, S., Laguía, F., Bracht, J. W. P., Cao, P., Molina‐Vila, M. Á., Karachaliou, N., et al. (2020) · Cancers · doi:10.3390/cancers12061475 · Cited by 102
Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition
Ding, H., Chen, Z., Wu, K., Huang, S. M., Wu, W., LeBoeuf, S. E., Pillai, R., Rabinowitz, J. D., & Papagiannakopoulos, T. Y. (2021) · Science Advances · doi:10.1126/sciadv.abk1023 · Cited by 96
The NRF2/KEAP1 Axis in the Regulation of Tumor Metabolism: Mechanisms and Therapeutic Perspectives
Panieri, E., Telkoparan‐Akillilar, P., Süzen, S., & Saso, L. (2020) · Biomolecules · doi:10.3390/biom10050791 · Cited by 101
Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism
Smolková, K., Mikó, E., Kovàcs, T., Leguina‐Ruzzi, A., Sipos, A., & Bai, P. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8024 · Cited by 101
Unveiling the role of KRAS in tumor immune microenvironment
Xu, M., Zhao, X., Wen, T., & Qu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116058 · Cited by 93
Self-citationGlutaminases regulate glutathione and oxidative stress in cancer
Matés, J. M., Campos-Sandoval, J. A., de los Santos-Jiménez, J., & Márquez, J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02838-8 · Cited by 91
LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases
Zhang, Y., Meng, Q., Sun, Q., Xu, Z., Zhou, H., & Wang, Y. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101131 · Cited by 91
“NRF2 addiction” in lung cancer cells and its impact on cancer therapy
Hammad, A., Namani, A., Elshaer, M., Wang, X. J., & Tang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.016 · Cited by 88
The Multifaceted Roles of NRF2 in Cancer: Friend or Foe?
Glorieux, C., Enriquez-Lara, C., González, C. D., Aguirre-Martínez, G. V., & Calderón, P. B. (2024) · Antioxidants · doi:10.3390/antiox13010070 · Cited by 97
Li, Y., Li, B., Xu, Y., Qian, L., Xu, T., Meng, G., Li, H., Wang, Y., Zhang, L., Jiang, X. W., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0042 · Cited by 90
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
Ma, Q., Zhang, W., Wu, K., & Shi, L. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02218-1 · Cited by 101
Self-citationThe Role of SLC7A11 in Cancer: Friend or Foe?
Li, S., Lu, Z., Sun, R., Guo, S., Gao, F., Cao, B., & Aa, J. (2022) · Cancers · doi:10.3390/cancers14133059 · Cited by 87
Bartolacci, C., Andreani, C., Elgammal, Y., & Scaglioni, P. P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.706650 · Cited by 85
Liaghat, M., Ferdousmakan, S., Mortazavi, S. H., Yahyazadeh, S., Irani, A., Banihashemi, S., Asl, F. S. S., Akbari, A., Farzam, F., Aziziyan, F., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01957-4 · Cited by 84
Soltis, A. R., Bateman, N. W., Liu, J., Nguyen, T. M., Franks, T. J., Zhang, X., Dalgard, C. L., Viollet, C., Somiari, S., Yan, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100819 · Cited by 78
Yokoyama, Y., Estok, T. M., & Wild, R. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0282 · Cited by 74
Xu, K., Ma, J., Hall, S. R. R., Peng, R., Yang, H., & Yao, F. (2023) · Theranostics · doi:10.7150/thno.80184 · Cited by 75
Koppula, P., Olszewski, K. L., Zhang, Y., Kondiparthi, L., Liu, X., Lei, G., Das, M., Fang, B., Poyurovsky, M. V., & Gan, B. (2021) · iScience · doi:10.1016/j.isci.2021.102649 · Cited by 74
Tanaka, I., Daydé, D., Tai, M.-C., Mori, H., Solis, L. M., Tripathi, S. C., Fahrmann, J. F., Ünver, N., Parhy, G., Jain, R., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab183 · Cited by 66
Riess, J. W., Frankel, P. H., Shackelford, D. B., Dunphy, M. P., Badawi, R. D., Nardo, L., Cherry, S. R., Lanza, I. R., Reid, J. M., Gonsalves, W. I., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.006 · Cited by 63
Chen, L., Zhang, W., Chen, D., Yang, Q., Sun, S., Dai, Z., Li, Z., Liang, X., Chen, C., Jiao, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01367-x · Cited by 62
Self-citationKRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Gu, M., Xu, T., & Chang, P. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006950 · Cited by 65
Osman, A. A., Arslan, E., Bartels, M. D., Michikawa, C., Lindemann, A., Tomczak, K. J., Yu, W., Sandulache, V. C., Ma, W., Shen, L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2747 · Cited by 63
Self-citationShen, Y. L., Chen, J.-Q., & Li, X. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101374 · Cited by 65
Liu, M., Gu, L., Zhang, Y., Li, Y., Zhang, L., Xin, Y., Wang, Y., & Xu, Z. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217025 · Cited by 62
Caeser, R., Egger, J. V., Chavan, S. S., Socci, N. D., Jones, C. B., Kombak, F. E., Asher, M., Roehrl, M. H. A., Shah, N., Allaj, V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29794-4 · Cited by 56
Molecular mechanisms of cell death in bronchopulmonary dysplasia
Deng, X., Bao, Z., Yang, X., Mei, Y., Zhou, Q., Chen, A., Yu, R., & Zhang, Y. (2022) · APOPTOSIS · doi:10.1007/s10495-022-01791-4 · Cited by 53
The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy
Wu, J., Liu, N., Chen, J., Tao, Q., Li, Q., Li, J., Chen, X., & Peng, C. (2024) · Research · doi:10.34133/research.0351 · Cited by 57
Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer
Ni, R., Li, Z., Li, L., Peng, D., Ming, Y., Li, L., & Liu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1143798 · Cited by 57
PPIA dictates NRF2 stability to promote lung cancer progression
Lü, W., Cui, J., Wang, W., Hu, Q., Xue, Y., Liu, X., Gong, T., Lu, Y., Ma, H., Yang, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48364-4 · Cited by 53
Detection and clinical significance of circulating tumor cells in colorectal cancer
Jiang, M., Jin, S., Han, J., Li, T., Shi, J., Zhong, Q., Li, W., Tang, W., Huang, Q., & Zong, H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00326-4 · Cited by 54
Metabolism in the progression and metastasis of brain tumors
Tyagi, A., Wu, S.-Y., & Watabe, K. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215713 · Cited by 55
Lang, L., Wang, F., Ding, Z., Zhao, X., Loveless, R., Xie, J., Shay, C., Qiu, P., Ke, Y., Saba, N. F., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02207-y · Cited by 48
LKB1 and cancer: The dual role of metabolic regulation
Li, T., & Zhu, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110872 · Cited by 46
SIRT7‐mediated modulation of glutaminase 1 regulates TGF‐β‐induced pulmonary fibrosis
Choudhury, M., Yin, X., Schaefbauer, K. J., Kang, J. H., Roy, B., Kottom, T. J., LIMPER, A. H., & Leof, E. B. (2020) · The FASEB Journal · doi:10.1096/fj.202000564r · Cited by 47
Xia, M., Li, X., Diao, Y., Du, B., & Li, Y. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100920 · Cited by 48
A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy
Zhang, D., Hou, Z., Aldrich, K. E., Lockwood, L. R., Odom, A. L., & Liby, K. T. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0210 · Cited by 46
Malvi, P., Janoštiak, R., Nagarajan, A. G., Cai, G., & Wajapeyee, N. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008439 · Cited by 46
Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer
Lu, H., Lou, H., Wengert, G., Paudel, R., Patel, N. R., Desai, S., Crum, B., Linton‐Reid, K., Chen, M., Li, D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101092 · Cited by 43
Fang, H., Dai, W., Gu, R., Zhang, Y., Li, J., Luo, W., Tong, S., Han, L., Wang, Y., Jiang, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01643-5 · Cited by 49
The Tumor Suppressor Kinase LKB1: Metabolic Nexus
Bourouh, M., & Marignani, P. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.881297 · Cited by 48
KEAP1/NRF2 (NFE2L2) mutations in NSCLC – Fuel for a superresistant phenotype?
Dempke, W. C. M., & Reck, M. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.006 · Cited by 43
Fahrmann, J. F., Tanaka, I., Irajizad, E., Mao, X., Dennison, J. B., Murage, E. N., Casabar, J. P., Mayo, J., Peng, Q., Çeliktaş, M., et al. (2022) · Cancers · doi:10.3390/cancers14102543 · Cited by 44
Islam, S. S., Qassem, K., Islam, S., Parag, R. R., Rahman, M. Z., Farhat, W. A., Yeger, H., Aboussekhra, A., Karakas, B., & Noman, A. S. M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05126-8 · Cited by 41
Liang, M., Wang, L., Sun, Z., Chen, X., Wang, H., Qin, L., Zhao, W., & Geng, B. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00875-7 · Cited by 44
Tamiya, Y., Matsumoto, S., Zenke, Y., Yoh, K., Ikeda, T., Shibata, Y., Kato, T., Nishino, K., Nakamura, A., Furuya, N., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.12.019 · Cited by 42
The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis
Occhiuto, C. J., Moerland, J. A., Leal, A. S., Gallo, K. A., & Liby, K. T. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2191 · Cited by 43
The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas
Mograbi, B., Heeke, S., & Hofman, P. M. (2021) · Diagnostics · doi:10.3390/diagnostics11020196 · Cited by 40
Metabolic Adaptation-Mediated Cancer Survival and Progression in Oxidative Stress
Tang, Y., Zhang, Z., Chen, Y., Qin, S., Zhou, L., Gao, W., & Shen, Z. (2022) · Antioxidants · doi:10.3390/antiox11071324 · Cited by 41
Hartmann, O., Reissland, M., Maier, C. R., Fischer, T., Prieto‐Garcia, C., Baluapuri, A., Schwarz, J. D., Schmitz, W., Garrido‐Rodríguez, M., Pahor, N., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641618 · Cited by 38
Ferroptosis in osteosarcoma: A promising future
Liu, X., Du, S., Wang, S., & Ye, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1031779 · Cited by 39
Oxidative Stress and Cancer Heterogeneity Orchestrate NRF2 Roles Relevant for Therapy Response
Gall‐Tros̆elj, K., Tomljanović, M., Jaganjac, M., Glavan, T. M., Gašparović, A. Č., Milković, L., Šunjić, S. B., Buttari, B., Profumo, E., Saha, S., et al. (2022) · Molecules · doi:10.3390/molecules27051468 · Cited by 38
Bhat, A. A., Moglad, E. H. O., Goyal, A., Afzal, M., Thapa, R., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Ali, H., Gaur, A., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123056 · Cited by 37
Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4–Induced Metabolic and Oxidative Stress
Hong, B.-J., Park, W., Kim, H.-R., Moon, J. W., Lee, H. Y., Park, J., Kim, S., Oh, Y., Roe, J., & Kim, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3511 · Cited by 36
Amino Acid Oncometabolism and Immunomodulation of the Tumor Microenvironment in Lung Cancer
Fahrmann, J. F., Vykoukal, J. V., & Ostrin, E. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00276 · Cited by 35
Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition
Hamada, S., Matsumoto, R., Tanaka, Y., Taguchi, K., Yamamoto, M. P., & Masamune, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041870 · Cited by 36
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 38
Self-citationTCA cycle-derived oncometabolites in cancer and the immune microenvironment
Sarkar, S., Chang, C.-I., Jean, J., & Wu, M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01186-y · Cited by 38
Metabolic Remodeling as a Way of Adapting to Tumor Microenvironment (TME), a Job of Several Holders
Serpa, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_1 · Cited by 35
Glutaminase inhibition as potential cancer therapeutics: current status and future applications
Cyriac, R., & Lee, K. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2290911 · Cited by 38
Metadata
- Authors
- Galan-Cobo, A., Sitthideatphaiboon, P., Qu, X., Poteete, A., Pisegna, M. A., Tong, P., Chen, P.-H., Boroughs, L. K., Rodriguez, M. L. M., Zhang, W., Parlati, F., Wang, J., Gandhi, V., Skoulidis, F., DeBerardinis, R. J., Minna, J. D., & Heymach, J. V.
- Affiliations
- 1Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Chulalongkorn University (TH)
- Shandong University (CN)
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- 619946 Hibiscus Dr., Jupiter, Florida.
- Calithera (United States) (US)
- Children's Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Heymach, John V.
- ORCID
- Venue
- Cancer Research
- Published
- 2019-07-01
- Volume
- 79
- Issue
- 13
- Pages
- 3251-3267
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC6606351
- OpenAlex
- W2943618951
- Cited by
- 292
- References
- 55
- Citations by year
- 2026: 33 · 2025: 36 · 2024: 37 · 2023: 41 · 2022: 55 · 2021: 45 · 2020: 35 · 2019: 10
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (P50CA07907, CA016672)
- HHS | NIH | National Center for Research ResourcesHHS | NIH | National Center for Research Resources (NCRR) (CA205150)
- Cancer Prevention and Research Institute of TexasCancer Prevention and Research Institute of Texas (CPRIT) (CP160652)
- American Association for Cancer ResearchAmerican Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- LKB1, Nrf2/Keap1 pathway, KRAS-mutant lung adenocarcinoma, metabolic reprogramming, glutamine addiction, glutaminase inhibition, CB-839, redox homeostasis, energy stress, reactive oxygen species, NADPH/NADP+ ratio, glutathione, TCA cycle
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Adenocarcinoma of Lung, AMP-Activated Protein Kinase Kinases, Adenosine Triphosphate, Animals, Carcinoma, Non-Small-Cell Lung, Energy Metabolism, Female, Glutaminase, Glutamine, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mutation, Tumor Cells, Cultured, Biomarkers, Tumor, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Apoptosis, Protein Serine-Threonine Kinases, Oxidative Stress, Xenograft Model Antitumor Assays, Cell Proliferation, NF-E2-Related Factor 2, Mice, Metabolic Networks and Pathways, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
